
Opinion|Videos|August 23, 2024
Treatment Sequencing With Androgen Receptor-Targeted Therapies for mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Key opinion leaders discuss considerations for sequencing androgen receptor-targeted therapies in metastatic castration-resistant prostate cancer, evaluating their benefits in first-line versus second-line treatment settings.
Advertisement
Episodes in this series

When treating with androgen receptor-targeted therapies, what are some of the considerations to make towards the sequencing of these agents and weighing their benefits in first line versus second line?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Experts discuss the challenge of detecting CIS in bladder cancer
2
Study shows durable 3-year outcomes with first-line gemcitabine/docetaxel in NMIBC
3
Phase 3 trial launches of CAIX-targeted radiopharmaceutical for ccRCC
4
Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation
5













